Research programme: therapeutics for mood and brain disorders - Janssen/University of Toronto

Drug Profile

Research programme: therapeutics for mood and brain disorders - Janssen/University of Toronto

Latest Information Update: 15 Sep 2014

Price : $50

At a glance

  • Originator Janssen Inc; University of Toronto
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Mood disorders

Most Recent Events

  • 15 Sep 2014 Janssen and University of Toronto agree to co-develop therapeutics in Canada for Mood disorders and Alzheimer's disease
  • 08 Sep 2014 Early research in Mood disorders in Canada (unspecified route)
  • 08 Sep 2014 Early research in Alzheimer's disease in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top